Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | BTK inhibitors in CLL

Florence Cymbalista • 19 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Ibrutinib Zanubrutinib

Florence Cymbalista, MD, of Hôpital Avicenne, Bobigny, France, explores clinical trials evaluating the use of second generation BTK inhibitors such as zanubrutinib and acalabrutinib for chronic lymphocytic leukemia (CLL), and their potential benefits over ibrutinib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Florence Cymbalista

2:30
Towards strategies to optimize outcomes in CLL
Florence Cymbalista • 7 Oct 2022
2:07
Moving towards time-limited treatment in frontline CLL
Florence Cymbalista • 7 Oct 2022
2:27
The importance of TP53 & IGHV testing before treatment initiation in CLL
Florence Cymbalista • 7 Oct 2022
1:33
Challenges in interpreting the results of genomic tests in CLL
Florence Cymbalista • 7 Oct 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals